Premium
Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?
Author(s) -
Brooks Kristina M.,
Sherman Elizabeth M.,
Egelund Eric F.,
Brotherton Amy,
Durham Spencer,
Badowski Melissa E.,
Cluck David B.
Publication year - 2019
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.2246
Subject(s) - dolutegravir , raltegravir , elvitegravir , integrase , integrase inhibitor , human immunodeficiency virus (hiv) , medicine , antiretroviral therapy , clinical trial , intensive care medicine , virology , viral load
The era of the integrase strand transfer inhibitors ( INSTI s) for the treatment of human immunodeficiency virus ( HIV ) infection began with raltegravir in 2007. Since that time, several other INSTI s have been introduced including elvitegravir, dolutegravir, and, most recently, bictegravir, that have shown great utility as part of antiretroviral regimens in both treatment‐naive and treatment‐experienced patients. At present, antiretroviral guidelines fully endorse the INSTI class as part of all first‐line treatment regimens. After 10 years of experience with INSTI s, newer agents are on the horizon such as cabotegravir and MK ‐2048 for potential use as either HIV pre‐exposure prophylaxis or maintenance therapy. This review provides a brief overview of the INSTI class including agents currently available and those still in development, reviews available data from both completed and ongoing clinical trials, and outlines simplification strategies using INSTI s.